FOXO4 10mg For Bodybuilding CAS:2460055-10-9

    What is FOXO4-DRI? The Molecular Underpinnings

    ●Core Target: Cellular Senescence. Senescent cells are "zombie" cells that have stopped dividing but resist death. They accumulate with age and stress (including intense training), secreting harmful inflammatory and tissue-degrading molecules collectively known as the Senescence-Associated Secretory Phenotype (SASP).

    ●FOXO4's Role: The FOXO4 protein is a transcription factor. In senescent cells, FOXO4 binds to another critical protein, p53. This interaction actively prevents p53 from triggering the cell's natural self-destruct (apoptosis) pathway, allowing the senescent cell to survive and perpetuate SASP.

    ●FOXO4-DRI's Clever Design: This synthetic peptide is engineered using D-amino acids in a retro-inverso sequence. This makes it highly resistant to degradation in the body. Its structure allows it to bind specifically to FOXO4 within senescent cells.

    ●Mechanism of Action: By binding FOXO4 with high affinity, FOXO4-DRI disrupts the FOXO4-p53 interaction. Freed p53 can then reactivate the apoptosis pathway, leading to the targeted self-destruction of the senescent cell. This is the essence of its senolytic activity – selectively killing senescent cells.

    1.High Specificity: Designed to target the FOXO4-p53 interaction primarily within senescent cells, theoretically minimizing off-target effects on healthy cells (though absolute specificity in humans is unproven).

    2.Senolytic Selectivity: Its core function is inducing apoptosis only in senescent cells, not proliferating or quiescent healthy cells.

    3.Peptide Nature: As a peptide, it faces challenges with oral bioavailability and requires injection (typically subcutaneous or intraperitoneal in studies).

    4.Experimental Status: Exists solely in the research domain. No approved pharmaceutical formulation exists. "FOXO4 10mg" implies a non-existent, standardized, commercially available product.

    5.D-Amino Acid Backbone: Provides exceptional resistance to enzymatic breakdown, potentially allowing less frequent dosing compared to natural peptides.

    6.Theoretical Transient Effect: Eliminates existing senescent cells but doesn't prevent new ones from forming. Effects are likely temporary, requiring periodic administration.

    The leap from mouse studies to bodybuilding benefits involves significant speculation. Potential applications hinge on the premise that exercise-induced senescent cells and SASP contribute to training plateaus, slowed recovery, and chronic inflammation:

    1.Accelerated Recovery: By eliminating senescent cells spewing SASP (rich in pro-inflammatory cytokines like IL-6, TNF-alpha), FOXO4-DRI could theoretically reduce exercise-induced inflammation and muscle damage perception, leading to faster return to peak training capacity.

    2.Enhanced Muscle Repair & Hypertrophy: Chronic SASP can impair satellite cell function (muscle stem cells crucial for repair/growth). Removing senescent cells might create a more favorable microenvironment for satellite cell activation and muscle protein synthesis, potentially improving hypertrophy response.

    3.Reduction of "Junk" Volume & Overtraining Risk: SASP contributes to systemic inflammation and tissue dysfunction. Reducing senescent burden could theoretically allow athletes to tolerate higher training volumes or intensities with less risk of overtraining symptoms.

    4.Improved Joint/Tendon Health: Senescent cells accumulate in connective tissues. Their removal might reduce SASP-driven degradation of collagen and other structural proteins, potentially alleviating joint/tendon pain and improving resilience.

    5.Metabolic Efficiency: Senescent cells can disrupt local metabolism. Clearing them might hypothetically improve nutrient partitioning and energy utilization within muscle tissue.

    ●Faster Inter-Session Recovery: Reduced muscle soreness and fatigue.

    ●Increased Training Frequency/Volume: Ability to train harder, more often.

    ●Improved Muscle Growth (Hypertrophy): Potentially better response to anabolic stimuli via improved satellite cell function and reduced catabolic SASP.

    ●Reduced Systemic Inflammation: Lower background inflammation potentially improving overall well-being and immune function.

    ●Enhanced Connective Tissue Resilience: Possible mitigation of training-related wear and tear on joints/tendons.

    ●Potential for Longer "Peak" Phases: By reducing cellular aging burden, might theoretically extend periods of optimal performance.

    Crucial Disclaimer: There are NO established, safe, or effective human protocols for FOXO4-DRI in bodybuilding or any other context. The following is extrapolated solely from preclinical (animal) studies and should be viewed as illustrative, NOT prescriptive.

    ●Dosage (Based on Murine Studies):

    ○Original 2017 study (Baar et al., Cell): Used ~5mg/kg in mice (equivalent to a massive and unrealistic human dose if scaled directly). Later studies often used lower doses.

    ○Hypothetical Human Equivalent Dose (HED): Calculating HED is complex and imprecise. Using standard conversion factors (based on body surface area), a mouse dose of 0.5-1 mg/kg might roughly translate to an HED in the range of 0.04 - 0.08 mg/kg. For an 80kg (176lb) individual, this would be approximately 3.2mg - 6.4mg.

    ○The "10mg" Myth: The origin of "10mg" is unclear but likely stems from internet speculation, misunderstanding of research doses, or arbitrary supplier labeling. It significantly exceeds most HED calculations from effective preclinical doses. There is no scientific basis for 10mg being an optimal or safe human dose.

    ●Administration: Requires injection (SC or potentially IM). Oral use is ineffective.

    ●Cycle:

    ○Preclinical studies often used intermittent dosing (e.g., once every few days or weeks).

    ○Hypothetical Bodybuilding Cycle: Given the transient effect (kills existing senescent cells, new ones form over time), a potential theoretical approach might involve short, periodic cycles. Example: 1-2mg administered every 3-5 days for 4-6 weeks, followed by an extended break (e.g., 8-12 weeks). This is pure conjecture.

    ●Half-Life: Data is limited. Its D-amino acid structure suggests significantly longer stability than natural peptides. Preliminary data indicates a half-life potentially in the range of 6-12 hours in mice. Human half-life is completely unknown but likely longer than many peptides due to its design. This could support less frequent dosing than daily peptides.

    ●PTC (Post-Treatment Considerations):

    ○Not PCT (Post-Cycle Therapy): FOXO4-DRI is not an anabolic steroid and does not suppress the HPTA. Traditional SERM/AI-based PCT is irrelevant.

    ○Monitoring: If used, vigilant monitoring would be prudent: CBC, CMP, inflammatory markers (CRP, IL-6), kidney/liver function, subjective recovery metrics.

    ○Supportive Measures: Focus remains paramount on foundational elements: optimal protein intake, calorie surplus/deficit as needed, micronutrient adequacy (esp. antioxidants), hydration, and structured rest. Senolytics are not a substitute.

    ○Long-Term Unknowns: The long-term consequences of repeated senolytic "purges" are completely unknown. Could it impair beneficial aspects of senescence (e.g., wound healing, tumor suppression)? Unclear.

    1.Not a Muscle-Building Drug: FOXO4-DRI is not anabolic. It does not directly stimulate muscle protein synthesis like testosterone or SARMs. Any potential muscle benefits are indirect and mediated through reducing senescence-induced dysfunction.

    2.Purely Experimental: Human data is virtually non-existent. Safety, efficacy, optimal dosing, and long-term effects in healthy humans are unknown. Most data comes from aged or diseased mouse models.

     3.Supply & Legality: Any "FOXO4 10mg" sold online is research chemical grade, produced in unregulated labs. Purity, sterility, and actual content are unreliable and potentially dangerous. It is not approved for human use by any regulatory body (FDA, EMA, etc.).

    4.Significant Risks:

    ○Off-Target Effects: Could theoretically kill non-senescent cells relying on FOXO4-p53.

    ○Immune Dysregulation: Senescent cells play roles in wound healing and immune responses. Removal could impair these.

    ○Unforeseen Long-Term Consequences: Disrupting fundamental aging biology pathways carries inherent risks we don't yet understand.

    ○Injection Risks: Infection, abscess, nerve/vessel damage.

    ○Unknown Toxicity Profile: Kidney, liver, or other organ toxicity cannot be ruled out.

    5.Ethical Void: Using unproven, potentially dangerous research chemicals for non-essential performance enhancement poses serious ethical questions regarding health risks and the integrity of sport.

Trade names	FOXO4, AFX, AFX1, MLLT7, forkhead box O4
CAS	2460055-10-9
Molar mass	5358.06
Formula	C250H432N86O86
Purity	Above 98%
Apprarance	10mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    FOXO4-DRI represents a groundbreaking scientific achievement in senolytic therapy, holding immense promise for treating age-related diseases. Its mechanism – selectively eliminating harmful senescent cells – is elegant and powerful in concept. However, its application in bodybuilding is currently speculative, premature, and fraught with significant, unknown risks.

    The "FOXO4 10mg" label is a misnomer and misrepresents a complex experimental peptide. There is no scientific basis for its use or dosing in healthy athletes. While the theoretical benefits related to recovery and inflammation reduction are intriguing, they remain firmly in the realm of hypothesis.

    Bodybuilders seeking enhanced recovery and performance should prioritize evidence-based, safe, and legal strategies: meticulous nutrition, periodized training, optimal sleep, stress management, and potentially established, well-researched supplements like creatine or beta-alanine. Experimenting with unproven, unregulated research chemicals like FOXO4-DRI carries substantial health risks far outweighing any potential, unconfirmed athletic benefit. The true potential of senolytics in sports medicine awaits rigorous, long-term human clinical trials – a process that has barely begun. Until then, extreme caution is the only rational approach.

Hot Tags: foxo4 10mg for bodybuilding cas:2460055-10-9, China foxo4 10mg for bodybuilding cas:2460055-10-9 manufacturers, suppliers, factory